153
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluation

Use of olanzapine in non-psychotic psychiatric disorders

&
Pages 667-680 | Published online: 24 Feb 2005

Bibliography

  • JANICAK PG, DAVIS JM, PRESKORN SH et al: Principles and Practice of Psychopharmacotherapy, (Edition 2). Williams & Wilkins Co, Baltimore (1997).
  • Mania: Clinical & Research Perspectives. Goodnick PJ (Ed.), APPI, Washington (1998).
  • ZARATE CA JR, TOHEN M, BALDESSARINI RJ: Clozapine in severe mood disorders. J Clin. Psychiatry (1995) 56:411–417.
  • TOHEN M, ZARATE CA, CENTORRINO F: Risperidone inthe treatment of mania. J. Clin. Psychiatry (1996) 57:249–253.
  • DWIGHT MM, KECK PE JR, STANTON SP et al: Antide-pressant activity and mania associated with risperi-done treatment of schizoaffective disorder. Lancet (1994) 344:554–555.
  • KECK PE JR, WILSON DR, STRAKOWSKI SM et al.: Clinical predictors of acute risperidone response in schizo-phrenia, schizoaffective disorder and psychotic mood disorders. J. Clin. Psychiatry (1995) 56:466–470.
  • RAVINDRAN AV, JONES BW, AL-ZAID K et al: Effective treatment of mania with olanzapine: 2 case reports. J Psychiatry Neurosci. (1997) 22 (5):345–346.
  • TOHEN M, SANGER TM, MCELROY SL et al.: Olanzapine versus placebo in the treatment of acute mania. Am. J Psychiatry (1999) 156(5):702–709.
  • TOHEN M, JACOBS TG, GRUNDY SL et al: Efficacy of olanzapine in acute bipolar mania. Arch. Gen. Psychiatry (2000) 57:841–849.
  • BERK M, ICHIM L, BROOK S: Olanzapine compared to lithium in mania: A double-blind randomized controlled trial. Int. Clin. Psychopharmacol (1999) 1 4 (6)339–343.
  • TOHEN M, BAKER RW, ALTSHULER L et al.: Olanzapine versus divalproex for the treatment of acute mania. Poster at ECNP, Munich, Germany (September 2000).
  • ZAJECKA J, WEISLER R, SOMMERVILLE W: Divalproex sodium vs. olanzapine for the treatment of mania in bipolar disorder. Poster At ACNP, San Juan, PR (December 2000).
  • POPE HG JR, MCELROY SL, KECK PE Jr. et al.: Valp r o ate in the treatment of acute mania. A placebo-controlled study. Arch. Gen. Psychiatry (1991) 48(1):62–68.
  • BOWDEN CL, BRUGGER AM, SWANN AC etal.: Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA (1994) 271 (12):918–924.
  • WEISLER RH, AHEARN EP, DAVIDSON JRT et al.: Adjunc-tive use of olanzapine in mood disorders: Five case reports. Ann. Clin. Psychiatry (1997) 9(4):259–262.
  • ANANTH J: Is olanzapine a mood stabilizer? Can. J Psychiatry (1999) 44(9):927–928.
  • KETTER TA, WINSBERG ME, DEGOLIA SG et al: Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states. J. Clin. Psychiatry (1998) 59 (2):83–85.
  • MCELROY SL, FRYE M, DENICOFF K et al.: Olanzapine intreatment-resistant bipolar disorder. J. Affect. Dis. (1998) 49:119–122.
  • SHARMA V, PISTOR L: Treatment of bipolar mixed statewith olanzapine. J. Psychiatry Neurosci. (1999) 24(1)40–44.
  • GUILLE C, SACHS GS, GHAEMI SN: A naturalisticcomparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder. J Clin. Psychiatry (2000) 61(9) :638–642.
  • TOHEN M, JACOBS TG, MEYERS TM et al: Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder. Int. J. Neuropsychophar-macology (2000) 3 (Suppl. 1):S335.
  • SANGER TM, TOHEN MF, JACOBS T et al: Long-term olanzapine treatment of mania. New Research, Annual Meeting American Psychiatric Association. Washington DC, USA (May 15–20 1999):190, NR444.
  • TOLLEFSON GD, SANGER TM, LU Y et al: Depressive signs and symptoms in schizophrenia. Arch. Gen. Psychiatry (1998) 55(3):250–258.
  • TOHEN MF, ZHANG F, SANGER TM et al.: Olanzapine versus haloperidol in schizoaffective bipolar disorder: A repeated-measures analysis. New Research, Annual Meeting American Psychiatric Association. Washington DC, USA (May 15–20 1999):185, NR429.
  • ADLI M, ROSSIUS W, BAUER M: Olanzapine in the treatment of depressive disorders with psychotic symptoms. Nervenarzt (1999) 70(0:68–71.
  • MALHI GS, CHECKLEY SA: Olanzapine in the treatment of psychotic depression. Br]. Psychiatry(1999) 174:460.
  • ROTHSCHILD A, BATES KS, BOEHRINGER KL et al.:Olanzapine response in psychotic depression. J Clin. Psychiatry (1999) 60(2):116–118.
  • ZARATE CA JR, NARENDRAN R, TOHEN M et al.: Clinicalpredictors of acute response with olanzapine in psychotic mood disorders. J Clin. Psychiatry (1998) 59 (1):24–28.
  • KOENIG F, BARG T, GRUENEWALD I et al.: Combinedtherapy using SSRI with neuroleptics in delusional depression. New Research, Annual Meeting American PsychiatricAssociation. (May 30 - June 4 1998)257, NR698.
  • TOLLEFSON GD, SHELTON RC, TOHEN MF et al.: Thestudy of olanzapine plus fluoxetine in treatment-resistant MDD without psychotic features. New Research, Annual Meeting American Psychiatric Associa-tion. Washington DC, USA (May 15–20 1999)193, NR455.
  • BORDON S, RASKIND MA: Clinical features andpharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology (1997) 48(5 Suppl. 6):S17–S24.
  • DEVANAND DP, MARDER K, MICHAELS KS et al.: A randomized, placebo-controlled dose-comparison trial of haloperidol for psychoses and disruptive behaviors in Alzheimer's disease. Am. J Psychiatry (1998) 155:1512–1520.
  • DE DEYN PP, RABHERU K, RASMUSSEN A et al.: A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology (1999) 53:946–955.
  • KATZ IR, JESTE DV, MINTZER JE et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J. Clin. Psychiatry (1999) 60:107–115.
  • KINON BJ, TARGUM SD, BASSON BR et al.: Olanzapine in the management of behavioral disturbances and/or psychosis in demented nursing home patients. Poster presentation at 12th European College of Neuropsychophar-macology (ECNP). London, UK (September 1999).
  • Data on file, Eli Lilly Laboratories.
  • STREET JS, CLARK WS, GANNON KS et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities. Arch. Gen. Psychiatry (2000) 57:968–976.
  • RUBIN M: Use of atypical antipsychotics in children with mental retardation, autism and other develop-mental disabilities. Psychiatric Ann. (1 9 9 7) 27 (3):219–220.
  • MALEK-AHMADI P, SIMONDS JF: Olanzapine for autistic disorder with hyperactivity. J. Am. Acad. Child Adolesc. Psychiatry (1998) 37 (9):902.
  • HORRIGAN JP, BARNHILL LF, COURVOISIE HE: Olanzapine in PDD. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:1166–1167.
  • ROYCHOUDHURY K, DEMB HB, ROSE F: Use of olanzapine in children with developmental disabilities and challenging behaviors. j Investigational Med. (1999) 47:165A.
  • KEMNER C, VAN ENGELAND H, TUYNMAN-QUA H: An open-label study of olanzapine in children with pervasive developmental disorder. Neuropsychophar-macology (1999) 9 (Suppl. 5):S287–S288.
  • POTENZA MN, HOLMES JP, KANES SJ et al. Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: An open-label pilot study. J. Clin. Psychopharmacol. (1999) 19 (1) 37–44.
  • CHANG KD, KETTER TA: Mood stabilizer augmentation with olanzapine in acutely manic children. J Child Adolesc. Psychopharmacol (2000) 10(1)45–49.
  • SOUTOLLO CA, SORTER MT, FOSTER KD et al.: Olanzapine in the treatment of adolescent acute mania: a report of seven cases. J Affect. Dis. (1999) 53 (3):279–283.
  • FRAZIER JA, BIEDERMAN J, JACOBS TG et al.: Olanzapine in the treatment of bipolar disorder in juveniles. AACAP/CACP. Chicago, IL, USA (October 1999).
  • POTENZA MN, WASYLINK S, LONGHURST JG et al: Olanzapine augmentation of fluox etine in the treatment of refractory obsessive-compulsive disorder. J. Clin. Psychopharmacol. (1998) 18 (5):423–424.
  • MARAZZITI D, PALLANTI S: Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am. J. Psychiatry (1999) 156(11):1834–1835.
  • POYUROVSKY M, DORFMAN-ETROG P, HERMESH H et al: Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (2000) 15(3):169–173.
  • DEGNER D, BLEICH S, KORNHUBER J et al: Olanzapine treatment of obsessive-compulsive disorder. Can. J. Psychiatry (2000) 45(4)393.
  • MOTTARD J-P, DE-LA-SABLONNIERE J-F: Olanzapine-induced obsessive-compulsive disorder. Am. J. Psychiatry (1999) 156(5):799–800.
  • WEISS EL, POTENZA MN, MCDOUGLE CJ et al.: Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin. Psychiatry (1999) 60:524–527.
  • KORAN LM, RINGOLD AL, ELLIOTT MA: Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry (2000) 61 (7):514–517.
  • SCHULZ SC, CAMLIN KL, BERRY SA et al: Olanzapinesafety and efficacy in patients with borderline person-ality disorder and comorbid dysthymia. Biol. Psychiatry (1999) 46:1429–1435.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.